Willamette Valley Cancer Institute and Research Center

Recent papers from Willamette Valley Cancer Institute and Research Center

1. Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLCNew England Journal of Medicine · 2026
2. Loncastuximab and Rituximab in Elderly Unfit/Frail Patients With Previously Untreated Diffuse Large B-Cell LymphomaBlood Advances · 2026
3. Durable response to tipifarnib in a patient with refractory head and neck cancer with a HRAS mutation: A case reportJournal of Case Reports and Images in Oncology · 2026
4. Summary of Research: Brentuximab Vedotin and Nivolumab in Combination with Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin LymphomaAdvances in Therapy · 2026
5. Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summaryFuture Oncology · 2026
6. Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi settingJournal of Geriatric Oncology · 2026
7. A single-arm, phase 2 study of neoadjuvant mirvetuximab soravtansine and carboplatin for FRα-expressing advanced-stage serous epithelial ovarian, fallopian tube, or primary peritoneal cancer (M25-231; NCT06890338; GOG-3115).Journal of Clinical Oncology · 2026
8. EPCORE NHL-6: Phase 2 study of subcutaneous (SC) epcoritamab as outpatient treatment for 2L+ relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).Journal of Clinical Oncology · 2026
9. Frameworks for improving comprehensive biomarker testing in NSCLC: A multi-stakeholder consensus.Journal of Clinical Oncology · 2026
10. A US real-world study of second-line outcomes in advanced ovarian cancer by first-line PARP inhibitor maintenance exposure.Journal of Clinical Oncology · 2026
11. Treatment patterns and PD-L1 testing among persistent, recurrent, or metastatic cervical cancer patients in the United States community oncology setting.Journal of Clinical Oncology · 2026
12. Fixed-duration subcutaneous (SC) mosunetuzumab (Mosun) in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Interim analysis and patient-reported outcomes (PROs) from the phase 2 MorningSun study.Journal of Clinical Oncology · 2026
13. Optec/Optal: A phase 2 study to evaluate outpatient (OP), step-up administration of teclistamab (Tec) or talquetamab (Tal) with prophylactic tocilizumab (prophyToci) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).Journal of Clinical Oncology · 2026
14. Radiotherapy use among locally advanced cervical cancer patients (LACC) in the United States community oncology setting.Journal of Clinical Oncology · 2026
15. Efficacy, safety, and cytokine profiling with addition of the toll-like receptor (TLR) 7/8 dual agonist EIK1001 to standard of care (SOC) first-line (1L) therapy: The phase 2 TeLuRide-005 trial in stage 4 NSCLC.Journal of Clinical Oncology · 2026
16. Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report.2026
17. Biomarker Testing Rates and Patterns in Patients With Metastatic Non–Small Cell Lung Cancer: A Prospective, Observational Study in Community PracticesJCO Precision Oncology · 2026
18. Preferred standard‐of‐care carfilzomib dosing in multiple myeloma: An international survey of haematologists/oncologistsBritish Journal of Haematology · 2026
19. 150TiP A phase Ib/II trial of a PD-1/VEGF bispecific antibody (PF-08634404) in combination with anticancer agents in first-line (1L) for advanced solid tumors (Symbiotic-Lung-20)ESMO Open · 2026
20. Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trialBlood · 2026